FTSE MIB
33.786,66 +40,00 (+0,12%) Dow Jones
37.945,42 +42,13 (+0,11%) Nasdaq
15.633,55 +28,07 (+0,18%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,92 -0,08 (-0,10%) Bitcoin EUR
54.667,96 +1.047,82 (+1,95%)
Cibus, Inc. (CBUS)
| Chiusura precedente | 17,11 |
| Aperto | 17,43 |
| Denaro | 16,75 x 300 |
| Lettera | 17,62 x 200 |
| Min-Max giorno | 17,01 - 17,43 |
| Intervallo di 52 settimane | 8,90 - 38,85 |
| Volume | |
| Media Volume | 66.601 |
| Capitalizzazione | 429,926M |
| Beta (5 anni mensile) | 1,95 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -25,95 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 23,00 |
- GlobeNewswire
Jim Collins to Join Cibus Board of Directors
Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. “Jim brings to Cibus immense knowledge and strategic vision on the directi
- GlobeNewswire
Cibus to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023. The presentation details are as follows: Presentation detailsDate: Monday, September 11, 2023Presentation Time: 9:30 – 10:00 AM ETWe
- GlobeNewswire
Cibus Reports Second Quarter 2023 Financial Results and Provides Business Update
Two gene editing pioneers closed merger to create a leading agricultural gene editing company with an expanded portfolio of patents, patents pending, and exclusive licenses to core technologies for gene editing of plants. Important greenhouse data continues to show promising results for Cibus’ first disease resistance trait for Sclerotinia resistance. Begins commercialization process for its three developed traits with initial transfers to customers: pod shatter reduction in canola and HT1 and H
